Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVN432 Nasal Spray in Healthy Subjects and Chronic Rhinosinusitis Patients
NCT07259538Phase 1Recruiting
- Sponsor
- VivaVision Biotech
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VVN432 in chronic rhinosinusitis (CRS), sponsored by VivaVision Biotech. Primary endpoints: Safety and Tolerability of VVN432 Nasal Spray in Healthy Subjects at 10 days and Safety and Tolerability of VVN432 Nasal Spray in CRS Patients at 35 days. Started Nov 2025; status: recruiting.
02
Drugs
VVN432
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT07259538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259538.